



Efficacy of Plasma Exchange and a Double-Plasma Molecular Absorption System for Treating Immune Checkpoint Inhibitor-Related Hepatitis

Ying Liu¹, Lihua Zheng¹, Wenxiong Xu¹, Qihuan Xu¹, Xinhua Li¹, Qu Lin², Lu Wang¹ and Jing Lai^{1,*}

¹Department of Infectious Diseases, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

²Department of Oncology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

*Corresponding author: Department of Infectious Diseases, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Email: laijing@mail.sysu.edu.cn

Received 2023 May 06; Revised 2023 August 27; Accepted 2023 September 03.

Abstract

Background: Immune checkpoint inhibitor (ICI)-related hepatitis has been increasing in the past decade.

Objectives: This study aimed to investigate the effectiveness of plasma exchange (PE) and a double-plasma molecular absorption system (DPMAS) for ICI-related hepatitis.

Methods: A retrospective analysis was conducted on patients with ICI-related hepatitis treated at the Third Affiliated Hospital of Sun Yat-Sen University (China). The collected data included biochemical indices, treatments, the use of an artificial liver support system (ALSS), and outcomes.

Results: From June 2021 to January 2023, 16 patients were treated and included in the analysis. Eight patients in group A received general support. The other 8 patients in group B received general support, plus 3 rounds of ALSS every 2 - 4 days (4 patients were treated with PE and the others with DPMAS + PE). There was no significant difference in age and treatment days between the two groups. Before treatment, there was no significant difference in direct bilirubin (DBIL), glutamine transpeptidase (GGT), alkaline phosphatase (ALP), aspartate transaminase, alanine transaminase (ALT), procalcitonin, the international normalized ratio (INR), model for end-stage liver disease scores, albumin, globulin, and hemocyte count between groups A and B (in all cases, $P > 0.05$). However, the total bilirubin (TBIL) of group B was significantly higher than that of group A ($P = 0.029$). After treatment, TBIL and DBIL were significantly decreased in group B (both $P < 0.05$), and group B had a significantly lower GGT ($P = 0.028$) and higher INR ($P = 0.004$) than group A. The ALP level of group B was also lower, but the difference was not significant ($P = 0.068$). No allergic reaction or severe adverse effect was observed.

Conclusions: Both PE and DPMAS + PE can effectively improve ICI-related hepatitis within the short term and are more effective for patients with hyperbilirubinemia. Liver function should be monitored continuously during treatment.

Keywords: Plasma Exchange (PE), double-Plasma Molecular Absorption System (DPMAS), Hepatitis, Immune Checkpoint Inhibitor (ICI), Efficacy

1. Background

Over the past decade, immune checkpoint inhibitors (ICIs) have been shown to be effective in the treatment of many malignancies, and their use is on the rise (1, 2). Immunosuppressive molecules are expressed in immune cells, and these can inhibit the immune system and prevent the body from forming an effective tumor immune response. In addition, immune checkpoints can be used by tumors in the tumor tissue to develop immune escape. Immune checkpoint inhibitors act on immune checkpoints to enhance the immune

response or attenuate immune suppression (1-3). However, an overactive immune response can lead to many immune-related adverse events (irAEs), which are being reported with increasing frequency. Skin, gastrointestinal and musculoskeletal systems, and lungs are most commonly affected by irAEs (4, 5).

Studies (5-7) have confirmed that ICI-related hepatitis is an immune-mediated hepatitis and a new type of drug-induced liver injury (DILI). The severity of hepatotoxicity is usually graded according to the common terminology criteria for adverse events (CTCAE) v. 4.03 (8), which uses total bilirubin (TBIL), gamma-glutamyl

transferase (GGT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) as evaluation factors. The drug-induced liver injury network (DILIN) severity index takes into account the international normalized ratio (INR), symptoms (ascites or encephalopathy), and other organ failures (9). Some studies have shown that ICI-related hepatitis often leads to the discontinuation of therapy and can be life-threatening in the absence of specific treatment (10,11). Corticosteroids are the most common initial treatment. However, even corticosteroids combined with immunosuppressant treatment do not effectively treat grade 3 and 4 liver injury, and deaths are commonly reported (5, 12, 13). Furthermore, long-term use of glucocorticoids may cause several adverse events (AEs) and superinfection (4,14).

The artificial liver support system (ALSS) has been used for treating severe liver damage. Both plasma exchange (PE) and a double-plasma molecular adsorption system (DPMAS) are widely utilized (15-17). With PE, the patient's plasma is separated from blood by a plasma separator to remove toxic substances adsorbed by plasma proteins and dissolved in the plasma, and then fresh frozen plasma containing coagulation factors and albumin (ALB) is transfused back into the body, along with the blood (15). In DPMAS, large- and medium-size soluble bilirubin and inflammatory mediators are removed when the filtered plasma is passed through a specific bilirubin adsorber and macroporous resin, respectively (16, 17). Studies have reported that both DPMAS and PE are promising treatments for severe viral hepatitis and liver failure, and DPMAS combined with PE is more effective than PE or DPMAS alone (16, 17). Still, clinical trial data (18-20) on the use of ALSS in patients with ICI-related hepatitis are limited (Table 1).

2. Objectives

This study aimed to investigate the effectiveness of PE and DPMAS for ICI-related hepatitis.

3. Methods

3.1. Patient Selection

This retrospective analysis was conducted on adult patients (≥ 18 years old) with ICI-related hepatitis treated at the Third Affiliated Hospital of Sun Yat-Sen University (SYSU), China. Diagnosis of ICI-related hepatitis was based on medical history, clinical features, and laboratory studies. The other inclusion criteria were: (1) no history of jaundice, hepatitis, or alcohol abuse; (2) no active viral infection, including viral hepatitis A, B, C, and E,

Epstein-Barr virus, herpes simplex virus, cytomegalovirus, varicella-zoster virus, and human immunodeficiency virus, excluded by laboratory testing; (3) normal levels of hemoglobin A (HbA), hemoglobin B (HbA2), and fetal hemoglobin (HbF); (4) negative Coombs test, Ham's test, and Rous test; (5) normal serum ceruloplasmin and copper levels; (6) no Kayser-Fleischer ring observed upon examination by an experienced ophthalmologist; (7) normal serum α -1-antitrypsin concentration, thyroid function tests, and alpha-fetoprotein level. The exclusion criteria were contraindications to ALSS, including active hemorrhage, disseminated intravascular coagulation (DIC), heart dysfunction, unstable postmyocardial or cerebral infarction, and allergic reaction to plasma, protamine, or heparin.

3.2. Treatment

The ICI treatment was stopped. Some patients only received comprehensive medical treatments, including general supportive care, as well as energy and vitamin supplementation.

The other patients were treated with an ALSS. Plasma exchange was performed with a plasma separator (MICROPLAS MPS 07, Belk Co. Ltd., Italy). About 2,000 mL of plasma was exchanged at each session. When DPMAS + PE was performed, the plasma flowed sequentially through an ion exchange resin (BS330, Zhuhai Health Sales Biotechnology Co., Ltd, China) and a neutral macroporous adsorption resin (HA330-II, Zhuhai Health Sales Biotechnology Co., China). Approximately 5 L was filtered each session. Then, PE was performed using plasma replacement (1,000 mL). The treatments were performed every 2 to 4 days.

Complaints and AEs that occurred during treatment were monitored and recorded. These included rash, fever, jaundice, fatigue, changes in appetite, abdominal distension, hepatic encephalopathy, ascites, hemoglobinuria, and hemorrhage.

3.3. Data Analysis

Based on CTCAE v. 4.03 (8), DILIN (9), and guidelines for the diagnosis and treatment of liver failure (China, 2018) (14), the following data were extracted from medical records: TBIL, direct bilirubin (DBIL), GGT, ALP, AST, ALT, ALB, GLB, INR, procalcitonin (PCT), white blood cell (WBC) count, hemoglobin (HGB) level, and platelet (PLT) count. The model for end-stage liver disease (MELD) score was calculated as $MELD = 3.78 \ln [TBIL \text{ (mg/dL)}] + 11.2 \ln (INR) + 9.6 \ln [\text{creatinine (mg/dL)}] + 6.4$ (pathogeny: Biliary or alcoholic 0, other 1) (21). All the patients were tested for antimitochondrial antibodies (AMA). The degree of DILI was divided into 4 grades, from 1 to 4 (8).

Table 1. Reports of Immune Checkpoint Inhibitor-Related Hepatitis Treated with the Artificial Liver Support System

	Case (n)	Diagnosis	Cancer Treatment	ALSS	Treatment Outcome
Chen et al. (18)	1	Hepatocellular carcinoma	Toripalimab	PE combined with CRRT	Died of multiple organ dysfunction syndrome 71 hours after liver transplantation
Wu et al. (19)	1	Hepatocellular carcinoma with pulmonary metastasis	Sorafenib with sequential 1 course of pembrolizumab	PE	Died of liver failure and its complications
Tan et al. (20)	1	Esophageal cancer with lymph node metastasis	2 courses of camrelizumab + capecitabine	5 rounds of PE with sequential DPMAS	Appetite improved, and TBIL decreased. Liver function was normalized 4 weeks after discharge.

Abbreviations: ALSS, artificial liver support system; DPMAS, double-plasma molecular absorption system; PE, plasma exchange; CRRT, continuous renal replacement therapy; TBIL, total bilirubin.

The data before and after the treatment are presented as mean \pm standard deviation (SD) and were compared by a *t*-test in SPSS v. 22.0 (IBM Corp., Armonk, NY, USA). *P*-values of < 0.05 were considered significant.

4. Results

From June 2021 to January 2023, 16 patients were included in the study. The ICIs used by the patients and the period of ICI treatment when hepatitis occurred are shown in Table 2. Table 2 also presents the chief complaints, ICI-related hepatitis grade, ALSS methods, and anti-immune therapy. Only 1 patient (case 10) was AMA-positive (titer 1:640). All the other patients were AMA-negative. All the patients were diagnosed with ICI-related hepatitis. No patient fulfilled the diagnostic criteria of autoimmune hepatitis. All of them stopped ICI treatment immediately. Eight patients in group A received general support. The other 8 patients in group B received general support, plus 3 rounds of ALSS every 2–4 days (4 patients received PE and 4 received DPMAS + PE). The mean age of group A was 49.6 ± 10.3 years, and that of group B was 52.6 ± 7.9 years ($t = 0.656$, $P = 0.523$). No significant difference was found in the number of treatment days between the two groups ($t = 0.000$, $P = 1.000$).

Before the treatment, there was no significant difference in DBIL, GGT, ALP, AST, ALT, PCT, INR, MELD, ALB, GLB, WBC count, PLT count, or HGB between the two groups ($P > 0.05$ in all cases). However, the TBIL of group B was significantly higher than that of group A ($P = 0.029$).

After treatment, TBIL and DBIL were significantly decreased in group B (both $P < 0.05$; Table 3). In addition, group B had a significantly lower GGT ($P = 0.028$) and higher INR ($P = 0.004$) than group A (Table 4). The ALP level of group B was also lower, but the difference was not significant ($P = 0.068$; Table 4).

The changes in TBIL, DBIL, GGT, ALP, and the MELD score during each session of ALSS are shown in Figure 1. All MELD

scores were below 21. No significant differences were found in AST, ALT, PCT, WBC count, INR, MELD score, ALB, GLB, PLT count, or HGB between the two groups ($P > 0.05$ in all cases; Table 4).

The chief complaints were improved. No allergic reaction or severe adverse effect was observed, including rash, fever, ascites, hemoglobinuria, hemorrhage, or hepatic encephalopathy.

5. Discussion

Based on the molecular mechanism, ICIs are commonly divided into three categories: Anti-cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) antibody, anti-programmed cell death receptor-1 (PD-1) antibody, and anti-programmed cell death ligand-1 (PDL-1) antibody. Anti-programmed cell death receptor-1 is expressed on the surface of T cells, while its ligand is expressed on the surfaces of tumor cells and myeloid suppressor cells. Immune checkpoint inhibitors inhibit the inflammatory activity of T lymphocytes by binding to the PDL1/PDL2 ligand, thereby improving the host's immune response against tumor cells (4, 10). However, an excessive immune response can cause liver damage. Reports of ICI-related hepatitis are increasing, and related drugs include camrelizumab, toripalimab, and nivolumab (18–20).

The results of our study showed that ICI-related hepatitis can occur with different ICIs. Peeraphatdit et al. (5) reported that the incidence of ICI-related hepatitis ranged from 0.7% to 16%, and the frequency was affected by treatment protocol, dosage, and patient characteristics. According to De Martin et al. (7), patients usually presented with mixed hepatocellular and cholestatic liver injury, with inflammation and necrosis of liver cells occurring at the peak of the disease.

Notably, our results revealed that serum TBIL and DBIL were significantly decreased after ALSS treatment

Table 3. Comparisons of Before and After Treatment Between the Groups

Items	Group A		Group B	
	<i>t</i>	P	<i>t</i>	P
TBIL (umol/L)	-0.239	0.815	3.038	0.013
DBIL (umol/L)	-0.155	0.879	3.062	0.010
GGT (U/L)	-0.062	0.952	1.753	0.119
ALP (U/L)	-0.226	0.852	1.664	0.136
AST (U/L)	1.200	0.250	1.014	0.328
ALT (U/L)	0.774	0.452	0.860	0.404
PCT (ng/mL)	0.548	0.598	0.809	0.432
WBC (E9/L)	0.161	0.875	-0.131	0.897
INR	1.374	0.209	-0.991	0.338
MELD	0.675	0.510	0.472	0.645
ALB (g/L)	-0.293	0.776	0.554	0.589
GLB (g/L)	0.167	0.870	1.194	0.252
PLT (E9/L)	-1.508	0.153	0.329	0.747
HGB (g/L)	0.774	0.454	1.524	0.150

Abbreviations: TBIL, total bilirubin; DBIL, direct bilirubin; GGT, glutamine transpeptidase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine transaminase; PCT, procalcitonin; WBC, white blood cell; INR, international normalized ratio; MELD, model for end-stage liver disease; ALB, albumin; PLT, platelet; HGB, hemoglobin.

Table 4. Comparison of Groups Before and After the Treatment

Items	Before Treatment				After Treatment			
	Group A	Group B	<i>t</i>	P	Group A	Group B	<i>t</i>	P
TBIL (umol/L)	115.51 ± 124.20	279.6 ± 145.4	2.427	0.029	131.6 ± 144.4	108.4 ± 65.2	-0.414	0.685
DBIL (umol/L)	77.13 ± 90.21	163.8 ± 74.0	2.102	0.054	84.5 ± 98.8	69.4 ± 45.4	-0.380	0.710
GGT (U/L)	550.3 ± 355.9	529.8 ± 540.9	-0.005	0.933	562.8 ± 419.4	186.8 ± 117.4	-2.442	0.028
ALP (U/L)	611.9 ± 574.1	545.9 ± 519.6	-0.234	0.819	682.9 ± 631.2	231.1 ± 128.3	-1.969	0.068
AST (U/L)	261.0 ± 149.0	413.1 ± 749.8	0.563	0.582	179.6 ± 120.7	133.3 ± 128.4	-0.744	0.469
ALT (U/L)	198.9 ± 253.3	406.1 ± 797.7	0.700	0.493	124.0 ± 103.3	153.5 ± 236.2	0.324	0.751
PCT (ng/mL)	1.85 ± 4.35	0.40 ± 0.37	-0.941	0.364	0.42 ± 0.46	0.28 ± 0.25	-0.705	0.499
WBC (E9/L)	7.73 ± 9.14	9.18 ± 6.88	0.359	0.725	7.08 ± 4.20	10.74 ± 8.13	0.998	0.338
INR	1.14 ± 0.40	1.17 ± 0.34	0.174	0.864	0.94 ± 0.08	1.30 ± 0.24	3.92	0.004
MELD	8.57 ± 10.88	11.40 ± 3.44	0.72	0.494	5.47 ± 7.09	8.81 ± 5.56	1.050	0.312
ALB (g/L)	35.0 ± 6.3	34.8 ± 3.7	-0.077	0.939	34.2 ± 2.5	33.6 ± 4.5	-0.331	0.746
GLB (g/L)	29.0 ± 6.2	25.5 ± 5.2	-1.029	0.239	28.4 ± 7.4	22.6 ± 4.5	-1.876	0.083
PLT (E9/L)	200 ± 69	198 ± 70	-0.043	0.966	265 ± 91	189 ± 37	-2.158	0.052
HGB (g/L)	113 ± 17	102 ± 10	-1.630	0.125	105 ± 21	94 ± 11	-1.356	0.200

Abbreviations: TBIL, total bilirubin; DBIL, direct bilirubin; GGT, glutamine transpeptidase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine transaminase; PCT, procalcitonin; WBC, white blood cell; INR, international normalized ratio; MELD, model for end-stage liver disease; ALB, albumin; PLT, platelet; HGB, hemoglobin.




Figure 1. Changes in blood indices and model for end-stage liver disease score before and after each session of the artificial liver support system

in group B (both $P < 0.05$). The ALP level was also lower, but the difference was not significant ($P = 0.068$). In addition, group B had a significantly lower GGT ($P = 0.028$) and higher INR ($P = 0.004$) than group A. As shown in Figure 1, the changes in TBIL, DBIL, GGT, ALP, and the MELD score during each session of ALSS support the fact that both PE and DPMAS + PE can retard the progression of the condition and inflammatory response. These results are consistent with those reported by Tan et al. (20). Larsen (22) also found that PE had a positive effect on ICI-related liver injury by decreasing bilirubin, creatinine, and inflammatory factors in the plasma. Reeves et al. (23) also reported that PE increased suppressor T function but decreased B cells. In that study, after treatment, the ratio of helper T cell type 1/2 (Th1/Th2) was increased. Chen et al. (24) and Li et al. (25) demonstrated a decline in the serum level of interleukin

(IL)-6, which can induce adhesion and aggregation of inflammatory cells to promote inflammation. Xia et al. (26) reported that the levels of WBC, PCT, IL-6, IL-10, and C-reactive protein were effectively decreased after ALSS (all $P < 0.05$). The proportions of patients with these abnormal inflammation-related indicators were also significantly reduced ($P < 0.05$). Taken together, our results and those of the aforementioned studies indicate that PE and DPMAS + PE can reduce hepatotoxicity and promote a beneficial environment for hepatocyte regeneration and repair.

As depicted in Tables 3 and 4 and Figure 1, all MELD scores were less than 21. Our results support that immediate termination of the ICI and timely treatment can improve the prognosis of ICI-related hepatitis. Furthermore, the results support monitoring liver function during ICI therapy.

Hepatotoxicity is a significant irAE. In most reported

cases of ICI-related hepatitis, the ICI was stopped, and immunosuppressive treatment started. Notably, in our study, 1 patient was positive for AMA (titer 1:640). The finding suggests the complexity of ICI-related hepatitis and that it can be caused by a variety of pathogenic mechanisms. Based on our results, we encourage the use of ALSS in the treatment of ICI-related hepatitis.

Because ICIs have become available for the treatment of cancers in China only recently, the number of cases of ICI-related hepatitis is limited, and the number of patients treated with ALSS is very small. Our study was a retrospective analysis of patients treated in our hospital. Thus, there was no sample size or power calculation. We plan a future study in which sample size calculation for statistical analysis will be performed with more cases. We also plan to include data such as liver histology and immunological items.

5.1. Conclusions

Many ICIs can cause ICI-related hepatitis, and the condition can present at different times during treatment. Both PE and DPMAS + PE effectively improve ICI-related hepatitis in the short term and may be more useful in patients with hyperbilirubinemia. Liver function should be monitored continuously during ICI therapy. Immediate ICI termination and timely treatment can improve the prognosis of ICI-related hepatitis.

Footnotes

Authors' Contribution: YL, JL, LHZ, WXX, and QHX contributed to the conception and design of the study. All the authors took part in the treatment of patients and collected the clinical data. YL, JL, LHZ, QHX, QL, and LW performed the data analysis. YL, JL, and WXX drafted the manuscript. YL and J L were responsible for revising the manuscript. All the authors read and approved the final manuscript.

Conflict of Interests: The authors declare no conflict of interest.

Data Reproducibility: The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available due to the original work of the author. All the data, tables, figures, etc., used in the manuscript were originally prepared by the authors; they have not been and will not be published or submitted elsewhere for publication.

Ethical Approval: The study was approved under the ethics approval code of the Ethical Committee of the

Third Affiliated Hospital of Sun Yat-Sen University (2020 02-009-01).

Funding/Support: This study was not supported by any specific grant from funding agencies in the public, commercial, or not-for-profit sector.

References

- Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*. 2020;**382**(9):810–21. [PubMed ID: 32101663]. <https://doi.org/10.1056/NEJMoa1910549>.
- Yuan J, Xu L, Zhou J, Shen L. Application of immune checkpoint inhibitors in hepatobiliary cancers. *ILIVER*. 2022;**1**(1):43–8. <https://doi.org/10.1016/j.iliver.2022.03.002>.
- Du M, Cai Y, Pang Y, Ji Y. A retrospective study of PD-L1 immunohistochemistry for hepatocellular carcinoma. *ILIVER*. 2022;**1**(3):187–93. <https://doi.org/10.1016/j.iliver.2022.08.005>.
- Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018;**4**(12):1721–8. [PubMed ID: 30242316]. [PubMed Central ID: PMC6440712]. <https://doi.org/10.1001/jamaoncol.2018.3923>.
- Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. *Hepatology*. 2020;**72**(1):315–29. [PubMed ID: 32167613]. <https://doi.org/10.1002/hep.31227>.
- Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. *N Engl J Med*. 2018;**378**(2):158–68. [PubMed ID: 29320654]. <https://doi.org/10.1056/NEJMra1703481>.
- De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. *J Hepatol*. 2018;**68**(6):1181–90. [PubMed ID: 29427729]. <https://doi.org/10.1016/j.jhep.2018.01.033>.
- U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute. *Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03*. 2010. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
- Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. *Drug Saf*. 2009;**32**(1):55–68. [PubMed ID: 19132805]. [PubMed Central ID: PMC3637941]. <https://doi.org/10.2165/00002018-200932010-00005>.
- Da Cunha T, Wu GY, Vaziri H. Immunotherapy-induced Hepatotoxicity: A Review. *J Clin Transl Hepatol*. 2022;**10**(6):1194–204. [PubMed ID: 36381098]. [PubMed Central ID: PMC9634765]. <https://doi.org/10.14218/JCTH.2022.00105>.
- Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. *Front Oncol*. 2020;**10**:91. [PubMed ID: 32117745]. [PubMed Central ID: PMC7033582]. <https://doi.org/10.3389/fonc.2020.00091>.
- Zhang D, Hart J, Ding X, Zhang X, Feely M, Yassan L, et al. Histologic patterns of liver injury induced by anti-PD-1 therapy. *Gastroenterol Rep (Oxf)*. 2020;**8**(1):50–5. [PubMed ID: 32467761]. [PubMed Central ID: PMC7244961]. <https://doi.org/10.1093/gastro/goz044>.

13. Vozy A, De Martin E, Johnson DB, Lebrun-Vignes B, Moslehi JJ, Salem JE. Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. *Eur J Cancer*. 2019;**123**:112–5. [PubMed ID: 31678768]. <https://doi.org/10.1016/j.ejca.2019.09.022>.
14. Yao J, Li S, Zhou L, Luo L, Yuan L, Duan Z, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. *J Clin Apher*. 2019;**34**(4):392–8. [PubMed ID: 30758886]. [PubMed Central ID: PMC6767528]. <https://doi.org/10.1002/jca.21690>.
15. Yuan S, Qian Y, Tan D, Mo D, Li X. Therapeutic plasma exchange: A prospective randomized trial to evaluate 2 strategies in patients with liver failure. *Transfus Apher Sci*. 2018;**57**(2):253–8. [PubMed ID: 29571962]. <https://doi.org/10.1016/j.transci.2018.02.001>.
16. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. [Guideline for diagnosis and treatment of liver failure]. *Zhonghua Gan Zang Bing Za Zhi*. 2019;**27**(1):18–26. Chinese. [PubMed ID: 30685919]. <https://doi.org/10.3760/cma.j.issn.1007-3418.2019.01.006>.
17. Guo X, Wu F, Guo W, Zhang J, Yang Y, Lu Y, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure. *J Int Med Res*. 2020;**48**(6). [PubMed ID: 32552092]. [PubMed Central ID: PMC7303772]. <https://doi.org/10.1177/0300060520932053>.
18. Chen GH, Wang GB, Huang F, Qin R, Yu XJ, Wu RL, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. *Transpl Immunol*. 2021;**66**:101386. [PubMed ID: 33744409]. <https://doi.org/10.1016/j.trim.2021.101386>.
19. Wu Z, Lai L, Li M, Zhang L, Zhang W. Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report. *Medicine (Baltimore)*. 2017;**96**(51):e9431. [PubMed ID: 29390572]. [PubMed Central ID: PMC5758274]. <https://doi.org/10.1097/MD.00000000000009431>.
20. Tan YW, Chen L, Zhou XB. Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature. *World J Clin Cases*. 2021;**9**(17):4415–22. [PubMed ID: 34141809]. [PubMed Central ID: PMC8173402]. <https://doi.org/10.12998/wjcc.v9.i17.4415>.
21. Yip TC, Lee HW, Wong VW, Wong GL, Tse YK, Lui GC, et al. Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. *J Gastroenterol Hepatol*. 2020;**35**(9):1610–8. [PubMed ID: 32032974]. <https://doi.org/10.1111/jgh.15007>.
22. Larsen FS. Reply to: "High volume plasma exchange in patients with acute liver failure". *J Hepatol*. 2016;**65**(3):647–8. [PubMed ID: 27255579]. <https://doi.org/10.1016/j.jhep.2016.05.033>.
23. Reeves HM, Winters JL. The mechanisms of action of plasma exchange. *Br J Haematol*. 2014;**164**(3):342–51. [PubMed ID: 24172059]. <https://doi.org/10.1111/bjh.12629>.
24. Chen G, Wu M, Wu B, Liu F, Liu J, Liu L. Effects of dual plasma molecular adsorption system on liver function, electrolytes, inflammation, and immunity in patients with chronic severe hepatitis. *J Clin Lab Anal*. 2019;**33**(7):e22926. [PubMed ID: 31206768]. [PubMed Central ID: PMC6757123]. <https://doi.org/10.1002/jcla.22926>.
25. Li YX, Ren YL, Fu HJ, Zou L, Yang Y, Chen Z. Hepatitis B Virus Middle Protein Enhances IL-6 Production via p38 MAPK/NF-kappaB Pathways in an ER Stress-Dependent Manner. *PLoS One*. 2016;**11**(7):e0159089. [PubMed ID: 27434097]. [PubMed Central ID: PMC4951109]. <https://doi.org/10.1371/journal.pone.0159089>.
26. Xia Q, Xu K, Yu L, Zhang H, Li L. Application value of artificial liver support system in the treatment of cytokine storm in patients with COVID-19. *Int Immunopharmacol*. 2021;**90**:107120. [PubMed ID: 33162345]. [PubMed Central ID: PMC7604162]. <https://doi.org/10.1016/j.intimp.2020.107120>.

Table 2. Clinical Characteristics of 16 Patients

No.	Sex	Age (y)	Diagnosis	ICIs	Chief Complaint	Grade of Hepatitis	ALSS	Anti-immune Therapy
1	M	35	Adenocarcinoma of the descending colon	5-Fluorouracil for 62 days, oxaliplatin + cetuximab for 5 courses	Eye and skin icterus, dark urine, poor appetite for 1 week	3	no	No glucocorticoid or immunosuppressant
2	F	37	Invasive ductal carcinoma of the right breast	DS-8201 for 3 courses	Recurrent abdominal distension for 3 months, exacerbation for 10 days	3	no	No glucocorticoid or immunosuppressant
3	M	41	Adenocarcinoma of ascending colon	Bevacizumab + FOLFIRINOX for 2 courses	Epigastric pain, poor appetite, fatigue for 4 weeks	3	no	No glucocorticoid or immunosuppressant
4	F	59	Adenocarcinoma of right upper lung	Pemetrexed disodium + sintilimab for 8 courses	Poor appetite, dark urine, eye and skin icterus for 20 days	3	no	Methylprednisolone 100 mg daily for 4 days
5	M	54	Clear cell carcinoma of the left kidney	Tislelizumab for 3 courses	Fatigue and poor appetite for 3 days	3	no	Methylprednisolone 40 mg daily for 6 days
6	F	54	Invasive ductal carcinoma of the right breast	Pertuzumab + trastuzumab + taxane for 3 courses, sequential pyrotinib + taxane for 1 course	Fatigue, poor appetite, dark urine, eye and skin icterus for 10 days	3	no	No glucocorticoid or immunosuppressant
7	F	60	Invasive ductal carcinoma of the right breast	Tirelizumab + bevacizumab + taxane for 3 courses, sequential bevacizumab + taxane for 3 courses	Eye and skin icterus for 11 days	4	no	No glucocorticoid or immunosuppressant
8	F	57	Papillary adenocarcinoma of the right breast	Exemestane + desulmab + abemaciclib for 1 course	Fatigue and poor appetite for 22 days	4	no	No glucocorticoid or immunosuppressant
9	M	42	Nasopharyngeal carcinoma	Camrelizumab + gemcitabine + cisplatin for 1 course	Eye and skin icterus for 2 weeks	4	DPMAS + PE	No glucocorticoid or immunosuppressant
10	M	47	Nasopharyngeal carcinoma	Gemcitabine + camrelizumab + nedaplatin for 1 course, sequential camrelizumab for 2 courses	Eye and skin icterus for 6 weeks	4	DPMAS + PE	Methylprednisolone 12.0 mg daily for 6 days
11	F	49	Adenocarcinoma of ascending colon	FOLFOX for 5 courses, sequential toripalimab for 2 courses	Eye and skin icterus for 7 days	4	DPMAS + PE	No glucocorticoid or immunosuppressant
12	M	66	Mucous adenocarcinoma of the gastric fundus	FOLFOX and nivolumab for 3 courses	Fatigue, poor appetite, dark urine for 3 days	4	PE	Mycophenolate mofetil 1 g daily for 3 days, sequential tacrolimus 3.0 mg + methylprednisolone 30 mg daily for 6 days
13	M	50	Mucous adenocarcinoma of the gastric body	Tirelizumab + gimeracil + tegafur + oteracil potassium for 3 courses	Skin and eyes icterus for more than 1 month	3	PE	Mycophenolate mofetil 1.0 g + dexamethasone 10.0 mg daily for 6 days
14	F	50	Peripheral adenocarcinoma of the left lung	Pemetrexed disodium + cisplatin, sequential sintilimab for the course each	Fatigue, cough, expectoration, and fever for 3 days	4	PE	No glucocorticoid or immunosuppressant
15	M	58	Clear cell carcinoma of the right kidney	Sintilimab for 7 courses, sequential sorafenib for 2 weeks	Poor appetite for 1 month, eye and skin icterus for 15 days	4	DPMAS + PE	No glucocorticoid or immunosuppressant
16	M	58	Adenocarcinoma of the right upper lung	Erlotinib for half a year	Eyes and skin icterus, gray stool for 20 days	4	DPMAS + PE	No glucocorticoid or immunosuppressant

Abbreviations: ICIs, immune checkpoint inhibitors; ALSS, artificial liver support system; DPMAS, double-plasma molecular absorption system; PE, plasma exchange.